128 related articles for article (PubMed ID: 36995690)
21. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
Bell EH; Pugh SL; McElroy JP; Gilbert MR; Mehta M; Klimowicz AC; Magliocco A; Bredel M; Robe P; Grosu AL; Stupp R; Curran W; Becker AP; Salavaggione AL; Barnholtz-Sloan JS; Aldape K; Blumenthal DT; Brown PD; Glass J; Souhami L; Lee RJ; Brachman D; Flickinger J; Won M; Chakravarti A
JAMA Oncol; 2017 Jun; 3(6):784-792. PubMed ID: 28097324
[TBL] [Abstract][Full Text] [Related]
22. Can Multistate Modeling of Local Recurrence, Distant Metastasis, and Death Improve the Prediction of Outcome in Patients With Soft Tissue Sarcomas?
Posch F; Leitner L; Bergovec M; Bezan A; Stotz M; Gerger A; Pichler M; Stöger H; Liegl-Atzwanger B; Leithner A; Szkandera J
Clin Orthop Relat Res; 2017 May; 475(5):1427-1435. PubMed ID: 28083752
[TBL] [Abstract][Full Text] [Related]
23. Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.
Buzdar AU; Suman VJ; Meric-Bernstam F; Leitch AM; Ellis MJ; Boughey JC; Unzeitig GW; Royce ME; Hunt KK
JAMA Oncol; 2019 Jan; 5(1):45-50. PubMed ID: 30193295
[TBL] [Abstract][Full Text] [Related]
24. Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303.
De Sanctis R; Giordano L; Colombo C; De Paoli A; Navarria P; Sangalli C; Buonadonna A; Sanfilippo R; Bertola G; Fiore M; Marrari A; Navarria F; Bertuzzi A; Casali PG; Basso S; Santoro A; Quagliuolo V; Gronchi A
Ann Surg Oncol; 2017 Dec; 24(13):3872-3879. PubMed ID: 29043525
[TBL] [Abstract][Full Text] [Related]
25. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
; Yee D; DeMichele AM; Yau C; Isaacs C; Symmans WF; Albain KS; Chen YY; Krings G; Wei S; Harada S; Datnow B; Fadare O; Klein M; Pambuccian S; Chen B; Adamson K; Sams S; Mhawech-Fauceglia P; Magliocco A; Feldman M; Rendi M; Sattar H; Zeck J; Ocal IT; Tawfik O; LeBeau LG; Sahoo S; Vinh T; Chien AJ; Forero-Torres A; Stringer-Reasor E; Wallace AM; Pusztai L; Boughey JC; Ellis ED; Elias AD; Lu J; Lang JE; Han HS; Clark AS; Nanda R; Northfelt DW; Khan QJ; Viscusi RK; Euhus DM; Edmiston KK; Chui SY; Kemmer K; Park JW; Liu MC; Olopade O; Leyland-Jones B; Tripathy D; Moulder SL; Rugo HS; Schwab R; Lo S; Helsten T; Beckwith H; Haugen P; Hylton NM; Van't Veer LJ; Perlmutter J; Melisko ME; Wilson A; Peterson G; Asare AL; Buxton MB; Paoloni M; Clennell JL; Hirst GL; Singhrao R; Steeg K; Matthews JB; Asare SM; Sanil A; Berry SM; Esserman LJ; Berry DA
JAMA Oncol; 2020 Sep; 6(9):1355-1362. PubMed ID: 32701140
[TBL] [Abstract][Full Text] [Related]
26. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
27. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
Spunt SL; Million L; Chi YY; Anderson J; Tian J; Hibbitts E; Coffin C; McCarville MB; Randall RL; Parham DM; Black JO; Kao SC; Hayes-Jordan A; Wolden S; Laurie F; Speights R; Kawashima E; Skapek SX; Meyer W; Pappo AS; Hawkins DS
Lancet Oncol; 2020 Jan; 21(1):145-161. PubMed ID: 31786124
[TBL] [Abstract][Full Text] [Related]
28. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
Pasquali S; Pizzamiglio S; Touati N; Litiere S; Marreaud S; Kasper B; Gelderblom H; Stacchiotti S; Judson I; Dei Tos AP; Verderio P; Casali PG; Woll PJ; Gronchi A;
Eur J Cancer; 2019 Mar; 109():51-60. PubMed ID: 30690293
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.
Safran HP; Winter K; Ilson DH; Wigle D; DiPetrillo T; Haddock MG; Hong TS; Leichman LP; Rajdev L; Resnick M; Kachnic LA; Seaward S; Mamon H; Diaz Pardo DA; Anderson CM; Shen X; Sharma AK; Katz AW; Salo J; Leonard KL; Moughan J; Crane CH
Lancet Oncol; 2022 Feb; 23(2):259-269. PubMed ID: 35038433
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant Radiotherapy is Associated with R0 Resection and Improved Survival for Patients with Extremity Soft Tissue Sarcoma Undergoing Surgery: A National Cancer Database Analysis.
Gingrich AA; Bateni SB; Monjazeb AM; Darrow MA; Thorpe SW; Kirane AR; Bold RJ; Canter RJ
Ann Surg Oncol; 2017 Oct; 24(11):3252-3263. PubMed ID: 28741123
[TBL] [Abstract][Full Text] [Related]
31. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
32. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
[TBL] [Abstract][Full Text] [Related]
33. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
Feng FY; Huang HC; Spratt DE; Zhao SG; Sandler HM; Simko JP; Davicioni E; Nguyen PL; Pollack A; Efstathiou JA; Dicker AP; Todorovic T; Margrave J; Liu YS; Dabbas B; Thompson DJS; Das R; Dignam JJ; Sweeney C; Attard G; Bahary JP; Lukka HR; Hall WA; Pisansky TM; Shah AB; Pugh SL; Shipley WU; Tran PT
JAMA Oncol; 2021 Apr; 7(4):544-552. PubMed ID: 33570548
[TBL] [Abstract][Full Text] [Related]
34. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Weidhaas JB; Harris J; Schaue D; Chen AM; Chin R; Axelrod R; El-Naggar AK; Singh AK; Galloway TJ; Raben D; Wang D; Matthiesen C; Avizonis VN; Manon RR; Yumen O; Nguyen-Tan PF; Trotti A; Skinner H; Zhang Q; Ferris RL; Sidransky D; Chung CH
JAMA Oncol; 2017 Apr; 3(4):483-491. PubMed ID: 28006059
[TBL] [Abstract][Full Text] [Related]
35. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.
Weiss AR; Chen YL; Scharschmidt TJ; Chi YY; Tian J; Black JO; Davis JL; Fanburg-Smith JC; Zambrano E; Anderson J; Arens R; Binitie O; Choy E; Davis JW; Hayes-Jordan A; Kao SC; Kayton ML; Kessel S; Lim R; Meyer WH; Million L; Okuno SH; Ostrenga A; Parisi MT; Pryma DA; Randall RL; Rosen MA; Schlapkohl M; Shulkin BL; Smith EA; Sorger JI; Terezakis S; Hawkins DS; Spunt SL; Wang D
Lancet Oncol; 2020 Aug; 21(8):1110-1122. PubMed ID: 32702309
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.
Canter RJ; Borys D; Olusanya A; Li CS; Lee LY; Boutin RD; Christensen SD; Tamurian RM; Monjazeb AM
Ann Surg Oncol; 2014 May; 21(5):1616-23. PubMed ID: 24554062
[TBL] [Abstract][Full Text] [Related]
37. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.
Jones CU; Pugh SL; Sandler HM; Chetner MP; Amin MB; Bruner DW; Zietman AL; Den RB; Leibenhaut MH; Longo JM; Bahary JP; Rosenthal SA; Souhami L; Michalski JM; Hartford AC; Amin PP; Roach M; Yee D; Efstathiou JA; Rodgers JP; Feng FY; Shipley WU
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):294-303. PubMed ID: 34481017
[TBL] [Abstract][Full Text] [Related]
38. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
[TBL] [Abstract][Full Text] [Related]
39. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma: multi-institutional analysis of 821 patients.
Sampath S; Schultheiss TE; Hitchcock YJ; Randall RL; Shrieve DC; Wong JY
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):498-505. PubMed ID: 20888702
[TBL] [Abstract][Full Text] [Related]
40. Older age impacts radiotherapy-related outcomes in soft tissue sarcoma.
Yuen NK; Li CS; Monjazeb AM; Borys D; Bold RJ; Canter RJ
J Surg Res; 2015 Dec; 199(2):494-504. PubMed ID: 26163324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
